NCT00530127View on ClinicalTrials.gov

A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Friedreich's Ataxia
Interventions
DRUG

placebo

Same dose and frequency as treatment

DRUG

deferiprone

100 mg/mL

DRUG

deferiprone

100 mg/mL

DRUG

placebo

Same dosage and frequency as study drug

DRUG

deferiprone

100 mg/mL

Trial Locations (6)

261

La Fundacion Para la Investigacion Biomedica, Madrid

1070

Hospital Erasme, Brussels

3052

Murdoch Children's Research Institute, Victoria

20133

"Fondazione IRCCS Istituto Neurologico C. Besta", Milan

75743

Hospital Necker-Enfants Malades, Paris

L8N 3Z5

McMaster University, Hamilton

Sponsors

Lead Sponsor

ApoPharma
All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT00530127 - A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia | Biotech Hunter | Biotech Hunter